Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro

Lung disease caused by Mycobacterium abscessus is increasing, and current clarithromycin-based treatment regimens are only moderately effective. Here, we determined the effect of clarithromycin-vancomycin combination against M. abscessus complex isolates in vitro. Synergy was found with a fractional...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Devika, Wu, Mu-Lu, Teo, Jeanette W. P., Dick, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700366/
https://www.ncbi.nlm.nih.gov/pubmed/28923867
http://dx.doi.org/10.1128/AAC.01298-17
_version_ 1783281108290371584
author Mukherjee, Devika
Wu, Mu-Lu
Teo, Jeanette W. P.
Dick, Thomas
author_facet Mukherjee, Devika
Wu, Mu-Lu
Teo, Jeanette W. P.
Dick, Thomas
author_sort Mukherjee, Devika
collection PubMed
description Lung disease caused by Mycobacterium abscessus is increasing, and current clarithromycin-based treatment regimens are only moderately effective. Here, we determined the effect of clarithromycin-vancomycin combination against M. abscessus complex isolates in vitro. Synergy was found with a fractional inhibitory concentration index (FICI) score of ≤0.5 and a 4- to 10-fold decrease in MIC.
format Online
Article
Text
id pubmed-5700366
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-57003662017-12-01 Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro Mukherjee, Devika Wu, Mu-Lu Teo, Jeanette W. P. Dick, Thomas Antimicrob Agents Chemother Susceptibility Lung disease caused by Mycobacterium abscessus is increasing, and current clarithromycin-based treatment regimens are only moderately effective. Here, we determined the effect of clarithromycin-vancomycin combination against M. abscessus complex isolates in vitro. Synergy was found with a fractional inhibitory concentration index (FICI) score of ≤0.5 and a 4- to 10-fold decrease in MIC. American Society for Microbiology 2017-11-22 /pmc/articles/PMC5700366/ /pubmed/28923867 http://dx.doi.org/10.1128/AAC.01298-17 Text en Copyright © 2017 Mukherjee et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Susceptibility
Mukherjee, Devika
Wu, Mu-Lu
Teo, Jeanette W. P.
Dick, Thomas
Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
title Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
title_full Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
title_fullStr Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
title_full_unstemmed Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
title_short Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
title_sort vancomycin and clarithromycin show synergy against mycobacterium abscessus in vitro
topic Susceptibility
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700366/
https://www.ncbi.nlm.nih.gov/pubmed/28923867
http://dx.doi.org/10.1128/AAC.01298-17
work_keys_str_mv AT mukherjeedevika vancomycinandclarithromycinshowsynergyagainstmycobacteriumabscessusinvitro
AT wumulu vancomycinandclarithromycinshowsynergyagainstmycobacteriumabscessusinvitro
AT teojeanettewp vancomycinandclarithromycinshowsynergyagainstmycobacteriumabscessusinvitro
AT dickthomas vancomycinandclarithromycinshowsynergyagainstmycobacteriumabscessusinvitro

Ejemplares similares